Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment

Study acronym: LIGHT 2
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Daniel A Tonetti, MD

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. Primary endpoint(s) modified Show 7 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 2026 to Sep 9, 2026
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints expanded, about 117 words
    • Site details revised
    • Collaborators expanded, about 4 words
    • Study title shortened, about 1 word
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this clinical trial is to test whether injecting lidocaine into two blood vessels of the brain can help treat chronic headaches (migraines)
Trial Details
NCT Number NCT07361549
Lead Sponsor Daniel A Tonetti, MD
Collaborators: SNIS Foundation, Stryker Neurovascular
Conditions
(from sponsor)		 Refractory Migraine, Headache
Related terms Headache, Migraine Disorders
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov